This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Yu, D.-C. Articles by Henderson, D. R. Search for Related Content PubMed PubMed Citation Articles by Yu, D.-C. Articles by Henderson, D. R.

The Addition of Adenovirus Type 5 Region E3 Enables Calydon Virus 787 to Eliminate Distant Prostate Tumor Xenografts

Calydon, Inc., Sunnyvale, California 94089

CV787, a novel highly prostate-specific replication-competent adenovirus with improved efficacy, was constructed. CV787 contains the prostate-specific rat probasin promoter, driving the adenovirus type 5 (Ad5) E1A gene, and the human prostate-specific enhancer/promoter, driving the E1B gene. To improve efficacy, we constructed CV787 such that it also contains the entire Ad5 E3 region. CV787 replicates in prostate-specific antigen (PSA)⁺ cells as well as wild-type adenovirus, but in PSA^- cells, CV787 replicates 10⁴–10⁵ times less efficiently. CV787 destroys PSA⁺ prostate cancer cells 10,000 times more efficiently than PSA^- cells. Incorporation of the Ad5 E3 region significantly improves the target cell killing ability or efficacy of CV787. In nu/nu mice carrying s.c. LNCaP xenografts, a single i.v. tail vein injection of CV787 eliminates 300-mm³ tumors within 4 weeks. CV787 could be a powerful therapeutic for human metastatic prostate cancer.

This article has been cited by other articles:

				E. V. Shashkova, K. Doronin, J. S. Senac, and M. A. Barry Macrophage Depletion Combined with Anticoagulant Therapy Increases Therapeutic Window of Systemic Treatment with Oncolytic Adenovirus Cancer Res., July 15, 2008; 68(14): 5896 - 5904. [Abstract] [Full Text] [PDF]

				J. Leja, H. Dzojic, E. Gustafson, K. Oberg, V. Giandomenico, and M. Essand A Novel Chromogranin-A Promoter-Driven Oncolytic Adenovirus for Midgut Carcinoid Therapy Clin. Cancer Res., April 15, 2007; 13(8): 2455 - 2462. [Abstract] [Full Text] [PDF]

				G. Glockzin, K. Mantwill, K. Jurchott, A. Bernshausen, A. Ladhoff, H.-D. Royer, B. Gansbacher, and P. S. Holm Characterization of the Recombinant Adenovirus Vector AdYB-1: Implications for Oncolytic Vector Development. J. Virol., April 1, 2006; 80(8): 3904 - 3911. [Abstract] [Full Text] [PDF]

				N. Ramesh, Y. Ge, D. L. Ennist, M. Zhu, M. Mina, S. Ganesh, P. S. Reddy, and D.-C. Yu CG0070, a Conditionally Replicating Granulocyte Macrophage Colony-Stimulating Factor-Armed Oncolytic Adenovirus for the Treatment of Bladder Cancer Clin. Cancer Res., January 1, 2006; 12(1): 305 - 313. [Abstract] [Full Text] [PDF]

				Y. Li, N. Idamakanti, T. Arroyo, S. Thorne, T. Reid, S. Nichols, M. VanRoey, G. Colbern, N. Nguyen, O. Tam, et al. Dual Promoter-Controlled Oncolytic Adenovirus CG5757 Has Strong Tumor Selectivity and Significant Antitumor Efficacy in Preclinical Models Clin. Cancer Res., December 15, 2005; 11(24): 8845 - 8855. [Abstract] [Full Text] [PDF]

				X. Li, J. Zhang, H. Gao, E. Vieth, K.-H. Bae, Y.-P. Zhang, S.-J. Lee, S. Raikwar, T. A. Gardner, G. D. Hutchins, et al. Transcriptional targeting modalities in breast cancer gene therapy using adenovirus vectors controlled by {alpha}-lactalbumin promoter Mol. Cancer Ther., December 1, 2005; 4(12): 1850 - 1859. [Abstract] [Full Text] [PDF]

				M. Zhu, J. A. Bristol, Y. Xie, M. Mina, H. Ji, S. Forry-Schaudies, and D. L. Ennist Linked Tumor-Selective Virus Replication and Transgene Expression from E3-Containing Oncolytic Adenoviruses J. Virol., May 1, 2005; 79(9): 5455 - 5465. [Abstract] [Full Text] [PDF]

				X. Li, Y.-P. Zhang, H.-S. Kim, K.-H. Bae, K. M. Stantz, S.-J. Lee, C. Jung, J. A. Jimenez, T. A. Gardner, M.-H. Jeng, et al. Gene Therapy for Prostate Cancer by Controlling Adenovirus E1a and E4 Gene Expression with PSES Enhancer Cancer Res., March 1, 2005; 65(5): 1941 - 1951. [Abstract] [Full Text] [PDF]

				Y. Wang, S. Thorne, J. Hannock, J. Francis, T. Au, T. Reid, N. Lemoine, D. Kirn, and G. Hallden A Novel Assay to Assess Primary Human Cancer Infectibility by Replication-Selective Oncolytic Adenoviruses Clin. Cancer Res., January 1, 2005; 11(1): 351 - 360. [Abstract] [Full Text] [PDF]

				R. L. Chu, D. E. Post, F. R. Khuri, and E. G. Van Meir Use of Replicating Oncolytic Adenoviruses in Combination Therapy for Cancer Clin. Cancer Res., August 15, 2004; 10(16): 5299 - 5312. [Abstract] [Full Text] [PDF]

				K. Toth, H. Djeha, B. Ying, A. E. Tollefson, M. Kuppuswamy, K. Doronin, P. Krajcsi, K. Lipinski, C. J. Wrighton, and W. S. M. Wold An Oncolytic Adenovirus Vector Combining Enhanced Cell-to-Cell Spreading, Mediated by the ADP Cytolytic Protein, with Selective Replication in Cancer Cells with Deregulated Wnt Signaling Cancer Res., May 15, 2004; 64(10): 3638 - 3644. [Abstract] [Full Text] [PDF]

				Q. Huang, X. Zhang, H. Wang, B. Yan, J. Kirkpatrick, M. W. Dewhrist, and C.-Y. Li A Novel Conditionally Replicative Adenovirus Vector Targeting Telomerase-Positive Tumor Cells Clin. Cancer Res., February 15, 2004; 10(4): 1439 - 1445. [Abstract] [Full Text] [PDF]

				L. Barzon, M. Boscaro, and G. Palu Endocrine Aspects of Cancer Gene Therapy Endocr. Rev., February 1, 2004; 25(1): 1 - 44. [Abstract] [Full Text] [PDF]

				Y. Jounaidi and D. J. Waxman Use of Replication-Conditional Adenovirus as a Helper System to Enhance Delivery of P450 Prodrug-Activation Genes for Cancer Therapy Cancer Res., January 1, 2004; 64(1): 292 - 303. [Abstract] [Full Text] [PDF]

				Y. Li, Y. Chen, J. Dilley, T. Arroyo, D. Ko, P. Working, and D.-C. Yu Carcinoembryonic antigen-producing cell-specific oncolytic adenovirus, OV798, for colorectal cancer therapy Mol. Cancer Ther., October 1, 2003; 2(10): 1003 - 1009. [Abstract] [Full Text]

				G. W. Demers, D. E. Johnson, V. Tsai, S.-F. Wen, E. Quijano, T. Machemer, J. Philopena, M. Ramachandra, J. A. Howe, P. Shabram, et al. Pharmacologic Indicators of Antitumor Efficacy for Oncolytic Virotherapy Cancer Res., July 15, 2003; 63(14): 4003 - 4008. [Abstract] [Full Text] [PDF]

				S. P. Balk, Y.-J. Ko, and G. J. Bubley Biology of Prostate-Specific Antigen J. Clin. Oncol., January 15, 2003; 21(2): 383 - 391. [Abstract] [Full Text] [PDF]

				K. Suzuki, R. Alemany, M. Yamamoto, and D. T. Curiel The Presence of the Adenovirus E3 Region Improves the Oncolytic Potency of Conditionally Replicative Adenoviruses Clin. Cancer Res., November 1, 2002; 8(11): 3348 - 3359. [Abstract] [Full Text] [PDF]

				D. M. Nettelbeck, A. A. Rivera, C. Balague, R. Alemany, and D. T. Curiel Novel Oncolytic Adenoviruses Targeted to Melanoma: Specific Viral Replication and Cytolysis by Expression of E1A Mutants from the Tyrosinase Enhancer/Promoter Cancer Res., August 15, 2002; 62(16): 4663 - 4670. [Abstract] [Full Text] [PDF]

				J. Zhang, N. Ramesh, Y. Chen, Y. Li, J. Dilley, P. Working, and D.-C. Yu Identification of Human Uroplakin II Promoter and Its Use in the Construction of CG8840, a Urothelium-specific Adenovirus Variant That Eliminates Established Bladder Tumors in Combination with Docetaxel Cancer Res., July 1, 2002; 62(13): 3743 - 3750. [Abstract] [Full Text] [PDF]

				K. A. Rauen, D. Sudilovsky, J. L. Le, K. L. Chew, B. Hann, V. Weinberg, L. D. Schmitt, and F. McCormick Expression of the Coxsackie Adenovirus Receptor in Normal Prostate and in Primary and Metastatic Prostate Carcinoma: Potential Relevance to Gene Therapy Cancer Res., July 1, 2002; 62(13): 3812 - 3818. [Abstract] [Full Text] [PDF]

				C.-L. Hsieh, L. Yang, L. Miao, F. Yeung, C. Kao, H. Yang, H. E. Zhau, and L. W. K. Chung A Novel Targeting Modality to Enhance Adenoviral Replication by Vitamin D3 in Androgen-independent Human Prostate Cancer Cells and Tumors Cancer Res., June 1, 2002; 62(11): 3084 - 3092. [Abstract] [Full Text] [PDF]

				K. Tsukuda, R. Wiewrodt, K. Molnar-Kimber, V. P. Jovanovic, and K. M. Amin An E2F-responsive Replication-selective Adenovirus Targeted to the Defective Cell Cycle in Cancer Cells: Potent Antitumoral Efficacy but No Toxicity to Normal Cell Cancer Res., June 1, 2002; 62(12): 3438 - 3447. [Abstract] [Full Text] [PDF]

				J. T. Mullen and K. K. Tanabe Viral Oncolysis Oncologist, April 1, 2002; 7(2): 106 - 119. [Abstract] [Full Text] [PDF]

				C. J. A. Ring Cytolytic viruses as potential anti-cancer agents J. Gen. Virol., March 1, 2002; 83(3): 491 - 502. [Abstract] [Full Text] [PDF]

				Y. Li, D.-C. Yu, Y. Chen, P. Amin, H. Zhang, N. Nguyen, and D. R. Henderson A Hepatocellular Carcinoma-specific Adenovirus Variant, CV890, Eliminates Distant Human Liver Tumors in Combination with Doxorubicin Cancer Res., September 1, 2001; 61(17): 6428 - 6436. [Abstract] [Full Text] [PDF]

				S. Matsubara, Y. Wada, T. A. Gardner, M. Egawa, M.-S. Park, C.-L. Hsieh, H. E. Zhau, C. Kao, S. Kamidono, J. Y. Gillenwater, et al. A Conditional Replication-competent Adenoviral Vector, Ad-OC-E1a, to Cotarget Prostate Cancer and Bone Stroma in an Experimental Model of Androgen-independent Prostate Cancer Bone Metastasis Cancer Res., August 1, 2001; 61(16): 6012 - 6019. [Abstract] [Full Text] [PDF]

				Y. Chen, T. DeWeese, J. Dilley, Y. Zhang, Y. Li, N. Ramesh, J. Lee, R. Pennathur-Das, J. Radzyminski, J. Wypych, et al. CV706, a Prostate Cancer-specific Adenovirus Variant, in Combination with Radiotherapy Produces Synergistic Antitumor Efficacy without Increasing Toxicity Cancer Res., July 1, 2001; 61(14): 5453 - 5460. [Abstract] [Full Text] [PDF]

				K. Doronin, M. Kuppuswamy, K. Toth, A. E. Tollefson, P. Krajcsi, V. Krougliak, and W. S. M. Wold Tissue-Specific, Tumor-Selective, Replication-Competent Adenovirus Vector for Cancer Gene Therapy J. Virol., April 1, 2001; 75(7): 3314 - 3324. [Abstract] [Full Text]

				T. P. Cripe, E. J. Dunphy, A. D. Holub, A. Saini, N. H. Vasi, Y. Y. Mahller, M. H. Collins, J. D. Snyder, V. Krasnykh, D. T. Curiel, et al. Fiber Knob Modifications Overcome Low, Heterogeneous Expression of the Coxsackievirus-Adenovirus Receptor That Limits Adenovirus Gene Transfer and Oncolysis for Human Rhabdomyosarcoma Cells Cancer Res., April 1, 2001; 61(7): 2953 - 2960. [Abstract] [Full Text]

				D.-C. Yu, Y. Chen, J. Dilley, Y. Li, M. Embry, H. Zhang, N. Nguyen, P. Amin, J. Oh, and D. R. Henderson Antitumor Synergy of CV787, a Prostate Cancer-specific Adenovirus, and Paclitaxel and Docetaxel Cancer Res., January 1, 2001; 61(2): 517 - 525. [Abstract] [Full Text]

				W. C. Russell Update on adenovirus and its vectors J. Gen. Virol., November 1, 2000; 81(11): 2573 - 2604. [Full Text]

				D. T. Curiel The Development of Conditionally Replicative Adenoviruses for Cancer Therapy Clin. Cancer Res., September 1, 2000; 6(9): 3395 - 3399. [Abstract] [Full Text]

				K. Doronin, K. Toth, M. Kuppuswamy, P. Ward, A. E. Tollefson, and W. S. M. Wold Tumor-Specific, Replication-Competent Adenovirus Vectors Overexpressing the Adenovirus Death Protein J. Virol., July 1, 2000; 74(13): 6147 - 6155. [Abstract] [Full Text]